Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 56,197.0 | 45,804.0 | 33,266.0 | 32,753.0 | 28,216.0 | 25,638.0 | 22,859.0 | 19,960.0 |
| Revenue growth | 22.7% | 37.7% | 1.6% | 16.1% | 10.1% | 12.2% | 14.5% | 6.2% |
| Cost of goods sold | 17,446.0 | 15,387.0 | 7,439.0 | 7,718.0 | 7,042.0 | 5,832.0 | 4,500.0 | 4,426.0 |
| Gross profit | 38,751.0 | 30,417.0 | 25,827.0 | 25,035.0 | 21,174.0 | 19,806.0 | 18,359.0 | 15,534.0 |
| Gross margin | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.3% | 80.3% | 77.8% |
| Selling, general and administrative | 12,349.0 | 11,299.0 | 6,942.0 | 7,399.0 | 6,295.0 | 5,881.0 | 6,387.0 | 7,724.0 |
| Research and development | 7,084.0 | 6,557.0 | 6,407.0 | 10,329.0 | 5,007.0 | 4,385.0 | 4,285.0 | 3,297.0 |
| EBITA | 22,963.0 | 11,415.0 | 11,445.0 | 7,628.0 | 9,995.0 | 10,332.0 | 7,956.0 | 3,814.0 |
| EBITA margin | 40.9% | 24.9% | 34.4% | 23.3% | 35.4% | 40.3% | 34.8% | 19.1% |
| Amortization of intangibles | 7,718.0 | 5,805.0 | 1,553.0 | 1,294.0 | 1,076.0 | 764.0 | 419.0 | 403.0 |
| EBIT | 15,245.0 | 5,610.0 | 9,892.0 | 6,334.0 | 8,919.0 | 9,568.0 | 7,537.0 | 3,411.0 |
| EBIT margin | 27.1% | 12.2% | 29.7% | 19.3% | 31.6% | 37.3% | 33.0% | 17.1% |
| Pre-tax income | 12,989.0 | 3,398.0 | 8,426.0 | 5,197.0 | 7,727.0 | 7,884.0 | 6,645.0 | 2,369.0 |
| Income taxes | 1,440.0 | -1,224.0 | 544.0 | -490.0 | 2,418.0 | 1,931.0 | 1,501.0 | 595.0 |
| Tax rate | 11.1% | | 6.5% | | 31.3% | 24.5% | 22.6% | 25.1% |
| Net income | 11,542.0 | 4,616.0 | 7,882.0 | 5,687.0 | 5,309.0 | 5,953.0 | 5,144.0 | 1,774.0 |
| Net margin | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | 22.5% | 8.9% |
| |
| Diluted EPS | $6.50 | $2.76 | $5.31 | $3.68 | $3.31 | $3.65 | $3.14 | $1.10 |
| Shares outstanding (diluted) | 1,777.0 | 1,673.0 | 1,484.0 | 1,546.0 | 1,603.0 | 1,631.0 | 1,637.0 | 1,610.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|